Yigeng Feng
Overview
Explore the profile of Yigeng Feng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang C, Cao H, Sun P, Chen L, Feng Y, Gao R
Am J Cancer Res
. 2024 Nov;
14(10):4830-4840.
PMID: 39553203
While androgen deprivation therapy (ADT) continues to be a fundamental aspect of prostate cancer treatment, the development of castration-resistant prostate cancer (CRPC) emphasizes the necessity for a more profound understanding...
2.
Cao H, Wang D, Gao R, Chen L, Feng Y, Sun P
J Tradit Complement Med
. 2024 Jan;
14(1):19-25.
PMID: 38223804
Background And Aim: Prostate cancer is a leading malignant tumor in men, associated with a high rate of mortality. Androgen deprivation therapy is commonly used to treat prostate cancer, which...
3.
Feng Y, Cao H, Wang D, Chen L, Gao R, Sun P
Acta Biochim Pol
. 2023 Dec;
70(4):817-822.
PMID: 38099475
Background: Prostate cancer is one of the most common cancers in men worldwide. This study aims to elucidate the roles of c-Jun N-terminal kinase (JNK) in the progression of castration-resistant...
4.
Cao H, Feng Y, Sun P, Chen L, Wang D, Gao R
J Cancer
. 2023 Aug;
14(12):2246-2254.
PMID: 37576403
Prostate cancer is the most common malignant tumor in men, accounting for one of the top five cancer incidences worldwide. However, there is no effective pharmacological treatment for advanced prostate...
5.
Cao H, Wu X, Gao R, Chen L, Feng Y, Wang D
J Cancer
. 2023 Aug;
14(12):2236-2245.
PMID: 37576395
QiLing Decoction (QLD) showed therapeutic effects against prostate cancer with an unclear underlying mechanism. This study explored the underlying mechanisms of QLD against castration-resistant prostate cancer (CRPC). Clinical specimens were...
6.
Sun P, Zhao W, Li H, Feng Y, Chen L, Cao H
Am J Cancer Res
. 2023 Jun;
13(5):2030-2040.
PMID: 37293174
Therapeutic resistance to androgen-deprivation therapy is a major challenge for prostate cancer therapy. The present study aims to explore the effects of poly (ADP-ribose) polymerase (PARP) inhibitor olaparib and STL127705...
7.
Feng Y, Cao H, Zhao W, Chen L, Wang D, Gao R
J Cancer
. 2023 Jan;
13(15):3652-3659.
PMID: 36606191
miR-143 is known to be downregulated in various cancer cells and tumors and generally plays a tumor-suppressor role. miR-143. However, the role of miR-143 in the mediation of the sensitivity...
8.
Feng Y, Cao H, Song Z, Chen L, Wang D, Gao R
Aging (Albany NY)
. 2022 Dec;
14(24):9942-9950.
PMID: 36541904
Abiraterone acetate has exhibited impressive results in improving progression-free survival of patients with metastatic castration-resistant prostate cancer. However, many patients may develop abiraterone resistance with a variable duration of response....
9.
Cao H, Wang D, Gao R, Li C, Feng Y, Chen L
PeerJ
. 2022 Jul;
10:e13481.
PMID: 35782093
QiLing decoction (QLD) is a traditional Chinese medicine compound. This study aims to explore the therapeutic effect of QLD in castration-resistant prostate cancer (CRPC) and its potential bio-targets. A total...
10.
Cao H, Wang D, Gao R, Feng Y, Chen L
Aging (Albany NY)
. 2022 Feb;
14(4):1812-1821.
PMID: 35193986
Tumor-associated macrophages (TAMs) are critical immune cells infiltrated into tumor. In present study, we evaluated the effects of Qi Ling (QL), a traditional Chinese medicine on paclitaxel resistance in prostate...